Emily M. Leproust Sells 2,402 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 2,402 shares of Twist Bioscience stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $98,265.82. Following the completion of the transaction, the chief executive officer now directly owns 662,692 shares of the company’s stock, valued at approximately $27,110,729.72. This represents a 0.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Twist Bioscience Stock Performance

TWST stock opened at $39.13 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The company has a market cap of $2.33 billion, a P/E ratio of -11.58 and a beta of 2.15. The stock’s fifty day moving average price is $46.33 and its 200-day moving average price is $45.43.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same period last year, the firm posted ($0.75) earnings per share. The business’s revenue for the quarter was up 24.1% on a year-over-year basis. On average, equities analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Institutional Trading of Twist Bioscience

Large investors have recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA boosted its stake in shares of Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after acquiring an additional 20,035 shares during the last quarter. Barclays PLC raised its holdings in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares during the period. FMR LLC grew its holdings in Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after purchasing an additional 12,327 shares during the period. Avanza Fonder AB purchased a new stake in Twist Bioscience in the fourth quarter worth about $1,059,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after buying an additional 21,357 shares during the period.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Scotiabank restated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird raised their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Barclays set a $58.00 target price on Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, TD Cowen restated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.